About Avilar
Avilar is a company based in Waltham (United States) founded in 2020 by James Kasuboski and Milind Deshpande.. Avilar has raised $75.28 million across 1 funding round from investors including RA Capital, Sanofi Ventures and Medical Excellence Capital. The company has 12 employees as of December 31, 2022. Avilar offers products and services including ATAC Platform and MTAC Platform. Avilar operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Waltham, United States
- Employees 12 as on 31 Dec, 2022
- Founders James Kasuboski, Milind Deshpande
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avilar Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$75.28 M (USD)
in 1 rounds
-
Latest Funding Round
$75.28 M (USD), Seed
Dec 14, 2020
-
Investors
RA Capital
& 3 more
-
Employee Count
12
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avilar
Avilar offers a comprehensive portfolio of products and services, including ATAC Platform and MTAC Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Harnesses ASGPR for degrading extracellular proteins in drug development.
Enables degradation of proteins using endogenous machinery for therapeutics.
Unlock access to complete
Unlock access to complete
Leadership Team
11 people
Product Management Team
2 people
Head Team
1 people
Co Team
1 people
Scientist Team
1 people
Unlock access to complete
Funding Insights of Avilar
Avilar has successfully raised a total of $75.28M through 1 strategic funding round. The most recent funding activity was a Seed round of $75.28 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $75.3M
-
First Round
First Round
(14 Dec 2020)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2020 | Amount | Seed - Avilar | Valuation | Sanofi Ventures , Medical Excellence Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Avilar
Avilar has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, Sanofi Ventures and Medical Excellence Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location | |
|
Capital is invested in early-stage life sciences ventures.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Avilar
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Avilar
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Avilar Comparisons
Competitors of Avilar
Avilar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Avilar
When was Avilar founded?
Avilar was founded in 2020.
Where is Avilar located?
Avilar is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of Avilar?
Daniel Grau is the current CEO of Avilar.
Is Avilar a funded company?
Avilar is a funded company, having raised a total of $75.28M across 1 funding round to date. The company's 1st funding round was a Seed of $75.28M, raised on Dec 14, 2020.
How many employees does Avilar have?
As of Dec 31, 2022, the latest employee count at Avilar is 12.
What does Avilar do?
Avilar was founded in 2020 and is based in Waltham, United States. A proprietary platform has been established in the biotech sector for developing extracellular protein degraders called ATACs. Disease-causing proteins are shuttled by these degraders from circulation to the endolysosome for breakdown. Broad applications are targeted across various diseases through this drug discovery approach.
Who are the top competitors of Avilar?
Avilar's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Avilar offer?
Avilar offers ATAC Platform and MTAC Platform.
Who are Avilar's investors?
Avilar has 4 investors. Key investors include RA Capital, Sanofi Ventures, Medical Excellence Capital, and Astellas Venture Management.